American Journal of Cardiology
Volume 105, Issue 8 , Pages 1053-1059 , 15 April 2010

Comparison of Bivalirudin and Unfractionated Heparin Plus Protamine in Patients With Coronary Heart Disease Undergoing Percutaneous Coronary Intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] Trial)

Received 30 September 2009 ,Revised 1 December 2009 ,Accepted 1 December 2009.

References 

  1. Briguori C, Di Mario C, De Gregorio J, Sheiban I, Vaghetti M, Colombo A. Administration of protamine after coronary stent deployment. Am Heart J. 1999;138:64–68
  2. Thuesen L, Andersen HR, Botker HE, Kristensen SD, Krusell LR, Lassen JF. In laboratory femoral sheath removal after heparin reversal by protamine after percutaneous coronary intervention. EuroInterv. 2005;1:66–70
  3. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein blockade compared with heparin and planned glycoprotein blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–863
  4. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351
  5. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation. 2007;116:2634–2653
  6. Kastrati A, Neumann F-J, Mehilli J, Byrne RA, Iijima R, Büttner HJ, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:688–696
  7. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Lancet. 2007;369:907–919
  8. Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE 2 trial. Am J Cardiol. 2007;100:1364–1369
  9. EPIC investigators. Use of the monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med. 1994;330:956–961
  10. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Lancet. 2007;369:907–919
  11. Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J. 2007;28:443–449
  12. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pre-treatment: the ISAR-REACT 2 randomized trial. JAMA. 2006;295:1531–1538
  13. Ni Ainle F, Preston RJ, Jenkins PV, Nel HJ, Johnson JA, Smith OP, et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood. 2009;114:1658–1665
  14. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol. 2007;49:1362–1368
  15. Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?. Circulation. 2007;116:2793–2801
  16. Sibbing D, Busch G, Braun S, Jawansky S, Schömig A, Kastrati A, et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation on patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J. 2008;29:1504–1509

 This study was supported by the investigators, and no company provided any financial support or drugs free of charge; we have no conflicts of interest to declare.

PII: S0002-9149(09)02829-X

doi: 10.1016/j.amjcard.2009.12.001

American Journal of Cardiology
Volume 105, Issue 8 , Pages 1053-1059 , 15 April 2010

Article Tools

* Image Usage & Resolution